Overview
Enfusion is a global, high-growth software-as-a-service, or SaaS, provider focused on transforming the investment management industry. Enfusion's solution is designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. Enfusion simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. This allows stakeholders throughout the entire client organization to interact more effectively with one another across the investment management lifecycle. Designed for the cloud from inception, Enfusion provides a flexible and simplified end-to-end solution that allows investment managers to focus their time and resources on investment performance. This enables us to build long-term partnerships with its clients, offering a solution that is not only tailored to meet their business needs today, but has the depth and breadth of capability to support them as they grow or enter new markets or asset classes.
Basic Stats
The share price of Enfusion, Inc. as of April 21, 2025 is $0.00 / share.
The Factor Analysis chart (below right) shows a view of Enfusion, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 1.03 |
| Beta | 2.21 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Enfusion, Inc. is $11.15. The forecasts range from a low of $9.74 to a high of $11.81. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Enfusion, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-03 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2022-10-03 | B of A Securities | Buy | Neutral | Downgrade |
| 2022-08-10 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-07-14 | Goldman Sachs | Neutral | Maintains | |
| 2022-07-06 | Piper Sandler | Overweight | Maintains | |
| 2022-05-13 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-05-13 | Credit Suisse | Neutral | Maintains | |
| 2022-03-25 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-03-25 | Credit Suisse | Neutral | Maintains | |
| 2022-03-21 | Stifel | Buy | Maintains | |
| 2022-03-16 | Goldman Sachs | Neutral | Maintains | |
| 2021-12-03 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-12-03 | Credit Suisse | Neutral | Maintains | |
| 2021-11-16 | William Blair | Outperform | Initiate | |
| 2021-11-15 | Stifel | Buy | Initiate | |
| 2021-11-15 | Piper Sandler | Overweight | Initiate | |
| 2021-11-15 | Morgan Stanley | Equal-Weight | Initiate | |
| 2021-11-15 | Goldman Sachs | Neutral | Initiate | |
| 2021-11-15 | Credit Suisse | Neutral | Initiate | |
| 2021-11-15 | B of A Securities | Buy | Initiate | |
| 2023-01-04 | B of A Securities | Neutral | Underperform | Downgrade |
| 2023-01-26 | Goldman Sachs | Neutral | Maintains | |
| 2023-03-15 | JP Morgan | Neutral | Initiate | |
| 2023-04-03 | Piper Sandler | Neutral | Initiate | |
| 2023-05-22 | Piper Sandler | Neutral | Neutral | Maintains |
| 2023-05-10 | Credit Suisse | Neutral | Maintains | |
| 2023-08-09 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-12-20 | Piper Sandler | Neutral | Neutral | Maintains |
| 2023-08-09 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2023-11-07 | UBS | Neutral | Initiate | |
| 2024-01-30 | JP Morgan | Neutral | Underweight | Downgrade |
| 2024-03-13 | B of A Securities | Underperform | Underperform | Maintains |
| 2024-02-28 | Goldman Sachs | Neutral | Sell | Downgrade |
| 2024-12-18 | Stifel | Buy | Buy | Maintains |
| 2024-12-23 | Piper Sandler | Neutral | Neutral | Maintains |
| 2025-01-13 | William Blair | Outperform | Market Perform | Downgrade |
